Results 31 to 40 of about 2,864 (172)

Six-Month Response to Delamanid Treatment in MDR TB Patients

Emerging Infectious Diseases, 2017
Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing ...
Cathy Hewison, Gabriella Ferlazzo, Zaza Avaliani, Armen Hayrapetyan, Sylvie Jonckheere, Zarema Khaidarkhanova, Erika Mohr, Animesh Sinha, Alena Skrahina, Debrah Vambe, Irina Vasilyeva, Nathalie Lachenal, Francis Varaine   +12 more
doaj   +1 more source

Thiazolidinedione–Pyrazolopyrimidinone Molecular Hybrids With Alkyl Spacers: Potential Antitubercular Agents Complemented by Molecular Modeling

ChemistrySelect, Volume 11, Issue 24, 25 June 2026.
We report the synthesis of 21 novel thiazolidinedione–pyrazolopyrimidinone derivatives (12a–u), prepared by coupling thiazolidinedione and pyrazolopyrimidinone pharmacophores through various alkyl linkers. The compounds were characterized spectroscopically and evaluated against the Mtb H37Rv strain, identifying compounds 5c and 5d as potent ...
Pule Seboletswe, Gobind Kumar, Nontobeko Gcabashe, Sanjeev Dhawan, Neha Manhas, Ankit, Audrey Jordaan, Digby F. Warner, Parvesh Singh   +8 more
wiley   +1 more source

Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid

Scientific Reports
The treatment of multidrug-resistant tracheobronchial tuberculosis poses challenges, and research investigating the efficacy of bedaquiline or delamanid as treatment for this condition is limited.
Qing Chen, Tao Huang, Liping Zou, Xianzhen Tang, Zhengyu Shi, Xinwei Wang, Huaige Wu, Jiying Sun, Xiaoli Lu, Li Liang, Liangshuang Jiang, Dafeng Liu, Shenjie Tang, Guihui Wu, Wei He   +14 more
doaj   +1 more source

Drug resistance to delamanid was detected in susceptible tuberculosis patient in Russia

Journal of Global Antimicrobial Resistance
AIM: To detect mutations in M. tuberculosis (MTB) associated with delamanid drug resistance in patients with tuberculosis (TB) in Russia. BACKGROUND: Delamanid is important in treatment of multi- and extensively drug-resistant TB.
Platon Eliseev, Irina Vasilyeva, Anatoly Vinokurov, Evgeny Kuznetsov, Kirill Baibekov, Anastasia Kazulina, Anastasia Samoilova   +6 more
doaj   +1 more source

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

Advanced Healthcare Materials, Volume 15, Issue 14, 10 April 2026.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales, Jessica Ingrid Marquez Cazorla, Renzo Marianito Marquez Cazorla, Aline Martins dos Santos, Jonatas Lobato Duarte, Letícia Oliveira Catarin Nunes, Túlio Custódio Reis, Lara Cerazi Salvador, Norival Alves Santos‐Filho, Rafael Miguel Sábio, Hélder A. Santos, Fernando Rogério Pavan   +11 more
wiley   +1 more source

Experience of Using Delamanid in the Treatment of Multiple Drug Resistant Tuberculosis

Туберкулез и болезни лёгких
The objective: to evaluate treatment results in MDR TB patients when delamanid is added to the treatment regimen.Subjects and Methods. 91 patients with multiple drug resistant pulmonary tuberculosis were included in the study, of which 36 people (39.6 ...
T. R. Bagdasaryan, M. A. Plekhanova, V. Yu. Smirnov, E. A. Grigorieva, Yu. I. Timakova, A. S. Goncharov   +5 more
doaj   +1 more source

Improving Genotype Imputation in High‐Dimensional Pharmacogenomics Using Multiple Imputation: Evaluation with Machine Learning Approaches

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 964-978, April 2026.
Multiple imputation is well‐established for handling missing data, yet its use in high‐dimensional genetic datasets remains limited. Using pharmacokinetic tuberculosis simulations and SNP data (1000 Genomes Project), we compared machine learning (ML) and traditional approaches (e.g., mean imputation and complete‐case analysis) for imputation and ...
Innocent G. Asiimwe, Tao You, Daniel F. Carr, Munir Pirmohamed, Geraint Davies, Andrea L. Jorgensen, on behalf of the UNITE4TB Consortium   +6 more
wiley   +1 more source

Rezultatele tratamentului tuberculozei multidrogrezistente cu utilizarea bedaquiline şi delamanid

Buletinul Academiei de Ştiinţe a Moldovei: Ştiinţe Medicale, 2021
Rezultatele tratamentului tuberculozei multidrogrezistente cu utilizarea bedaquiline şi delamanid Articolul prezintă rezultatele unei analize a eficacităţii şi siguranţei bedaquilinei şi delamanidului la pacienţii cu tuberculoză multidrogrezistentă (TB ...
Rafig Bayramov, Jeyhun Ismayilzada, Orkhan Suleymanov   +2 more
doaj   +1 more source

Exploring Novel Nitrofuryl‐1,3,4‐Thiadiazole‐Based Derivatives: Design, Synthesis, and Evaluation of In Vitro Leishmanicidal and Trypanocidal Activity

Archiv der Pharmazie, Volume 359, Issue 3, March 2026.
In a series of substituted 1‐[5‐(5‐nitrofuran‐2‐yl)‐1,3,4‐thiadiazol‐2‐yl]piperidine‐4‐carboxamides evaluated for in vitro antileishmanial and antitrypanosomal activity, compound 18 emerged as the most promising derivative, showing submicromolar anti‐parasitic effects targeting diverse Leishmania and Trypanosoma species and acceptable selectivity ...
Alireza Mousavi, Martina Slapničková, Maryam Norouzbahari, Sarah D'Alessandro, Parham Foroumadi, Fariba Peytam, Federica Perego, Eva Doleželová, Zahra Emamgholipour, Maliheh Barazandeh Tehrani, Seyed Esmaeil Sadat‐Ebrahimi, Elahe Hosseinzadeh, Elmira Meghrazi Ahadi, Loghman Firoozpour, Hamidreza Bijanzadeh, Nicoletta Basilico, Alena Zíková, Alireza Foroumadi   +17 more
wiley   +1 more source

Adduct Formation of Delamanid with NAD in Mycobacteria

Antimicrobial Agents and Chemotherapy, 2020
Delamanid (DLM), a nitro-dihydroimidazooxazole derivative currently approved for pulmonary multidrug-resistant tuberculosis (TB) therapy, is a prodrug activated by mycobacterial 7,8-didemethyl-8-hydroxy 5-deazaflavin electron transfer coenzyme (F 420 )-dependent nitroreductase (Ddn).
Mikayo Hayashi, Akihito Nishiyama, Ryuki Kitamoto, Yoshitaka Tateishi, Mayuko Osada-Oka, Yukiko Nishiuchi, Shaban A. Kaboso, Xiuhao Chen, Mamoru Fujiwara, Yusuke Inoue, Yoshikazu Kawano, Masanori Kawasaki, Tohru Abe, Tsutomu Sato, Kentaro Kaneko, Kimiko Itoh, Sohkichi Matsumoto, Makoto Matsumoto   +17 more
openaire   +3 more sources